However, we found altered ERK-phosphorylation induced by FGFR-inhibition in all patients thus implying that FGF signalling can modulate MAPK-phosphorylation in RAS-mutant (Patient 1,3,4) as well as in RAS-wild-type tumours (Patient 2). Here, EPHB2 is linked to neoplasm.